


Accepted Manuscript

Title: Decitabine in Combination with Donor Lymphocyte Infusions can Induce Remissions in relapsed Myeloid Malignancies with Higher Leukemic Burden after Allogeneic Hematopoietic Cell Transplantation



Authors: Sebastian Sommer, Marjan Cruijisen, Rainer Claus, Hartmut Bertz, Ralph Wäsch, Reinhard Marks, Robert Zeiser, Lioudmila Bogatyreva, Nicole M.A. Blijlevens, Annette May, Justus Duyster, Gerwin Huls, Walter J.F.M. van der Velden, Jürgen Finke, Michael Lübbert

PII: S0145-2126(18)30149-8
DOI: <https://doi.org/10.1016/j.leukres.2018.07.005>
Reference: LR 5990

To appear in: *Leukemia Research*

Received date: 22-3-2018
Revised date: 26-6-2018
Accepted date: 7-7-2018

Please cite this article as: Sommer S, Cruijisen M, Claus R, Bertz H, Wäsch R, Marks R, Zeiser R, Bogatyreva L, Blijlevens NMA, May A, Duyster J, Huls G, van der Velden WJFM, Finke J, Lübbert M, Decitabine in Combination with Donor Lymphocyte Infusions can Induce Remissions in relapsed Myeloid Malignancies with Higher Leukemic Burden after Allogeneic Hematopoietic Cell Transplantation, *Leukemia Research* (2018), <https://doi.org/10.1016/j.leukres.2018.07.005>

This is a PDF file of an unedited manuscript that has been accepted for publication. As a service to our customers we are providing this early version of the manuscript. The manuscript will undergo copyediting, typesetting, and review of the resulting proof before it is published in its final form. Please note that during the production process errors may be discovered which could affect the content, and all legal disclaimers that apply to the journal pertain.

Decitabine in Combination with Donor Lymphocyte Infusions can Induce Remissions in relapsed Myeloid Malignancies with Higher Leukemic Burden after Allogeneic Hematopoietic Cell Transplantation

Sebastian Sommer^{1,8}, Marjan Cruijssen², Rainer Claus^{1,8}, Hartmut Bertz¹, Ralph Wäsch¹, Reinhard Marks¹, Robert Zeiser¹, Lioudmila Bogatyreva⁴, Nicole M.A. Blijlevens², Annette May³, Justus Duyster^{1,5,6}, Gerwin Huls⁷, Walter J.F.M. van der Velden², Jürgen Finke¹, Michael Lübbert^{1,5,6}.

¹Department of Hematology-Oncology, Medical Center, Faculty of Medicine, University of Freiburg, Freiburg, Germany

²Department of Hematology, Radboud University Medical Center, Nijmegen, The Netherlands

³Institute of Pathology, Medical Center, Faculty of Medicine, University of Freiburg, Freiburg, Germany

⁴Institute for Medical Biometry and Statistics, University of Freiburg, Freiburg, Germany

⁵German Cancer Consortium (DKTK), Freiburg, Germany

⁶German Cancer Research Center (DKFZ), Heidelberg, Germany

⁷Department of Hematology, University Medical Center Groningen, Groningen, The Netherlands

⁸current address: ¹Department of Hematology-Oncology, Augsburg Medical Center, Augsburg, Germany

Correspondence:

M Lübbert, Division of Hematology, Oncology and Stem Cell Transplantation, University of Freiburg Medical Center, Hugstetter Str. 55, 79106 Freiburg, Germany. E-mail: michael.luebbert@uniklinik-freiburg.de

Highlights:

- **26 patients with overt hematological relapse after allo-HCT were evaluable**
- **DAC + DLI proved feasible and effective in relapse after allo-HCT**
- **Overall response rate 19% (CR/CRi (4/26); PR (1/26)), stable disease in 54% (14/26)**
- **Median overall survival was 4.7 months**

Download English Version:

<https://daneshyari.com/en/article/8453253>

Download Persian Version:

<https://daneshyari.com/article/8453253>

[Daneshyari.com](https://daneshyari.com)